Compugen Ltd. (CGEN)
| Market Cap | 186.61M -3.2% |
| Revenue (ttm) | 74.00M +234.2% |
| Net Income | 35.19M |
| EPS | 0.37 |
| Shares Out | 94.72M |
| PE Ratio | 5.28 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 158,898 |
| Open | 1.970 |
| Previous Close | 1.960 |
| Day's Range | 1.950 - 1.995 |
| 52-Week Range | 1.430 - 3.235 |
| Beta | 2.79 |
| Analysts | Strong Buy |
| Price Target | 4.60 (+133.5%) |
| Est. Earnings | Nov 9, 2026 |
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/T... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CGEN stock is "Strong Buy." The 12-month stock price target is $4.6, which is an increase of 133.50% from the latest price.
News
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today...
Compugen Transcript: KOL event
COM701 is being tested as maintenance for selected platinum-sensitive ovarian cancer patients, with interim PFS expected by Q1 2027. UniGenX extends the discovery platform into multi-omics TAA discovery, while Q&A highlighted tolerability, patient selection, and validation needs.
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
HOLON, Israel, Sept. 22, 2026 /PRNewswire/ -- Compugen Ltd.
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd.
Compugen Earnings Call Transcript: Q2 2026
Q2 2026 saw steady clinical and financial progress, with key trials advancing and partnerships expanding. Revenue doubled year-over-year, cash runway extends into 2029, and major collaborations with AstraZeneca and Gilead continue to drive pipeline momentum.
Compugen Earnings release: Q2 2026
Compugen released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Compugen reports Q2 EPS (7c), consensus (9c)
Reports Q2 revenue $2.6M, consensus $1.28M. As of June 30 Compugen (CGEN) had approximately $125.3M in cash, cash equivalents, short-term bank deposits, and investment in marketable securities. Compug...
Compugen Reports Second Quarter 2026 Results
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027 Trial-in-progress poster on MAIA-ovarian presented at the ESMO...
Compugen Slides: Corporate presentation
Compugen has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Compugen to Participate in BTIG Biotechnology Conference 2026
HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, t...
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI...
Compugen management to meet virtually with Lake Street
Virtual Meeting to be held on July 21 hosted by Lake Street.
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/...
Compugen Transcript: Fireside chat
The discussion highlighted a unique computational platform for early-stage target discovery in immuno-oncology, emphasizing rigorous validation, clinical translation, and strategic flexibility. Key milestones include the MAIA-ovarian study readout in Q1 2027 and ongoing partnerships with major pharma companies.
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery pow...
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, to...
Compugen price target lowered to $5 from $13 at Leerink
Leerink lowered the firm’s price target on Compugen (CGEN) to $5 from $13 and keeps an Outperform rating on the shares.
Compugen Transcript: Stifel 2026 Targeted Oncology Virtual Forum
AI-driven immuno-oncology discovery has led to a robust pipeline, including COM701 in pivotal ovarian cancer trials, GS-0321 in partnership with Gilead, and rilvegostomig with AstraZeneca in 11 phase III studies. Recent monetization and milestones provide financial runway into 2029.
Compugen files $400M mixed securities shelf
16:04 EDT Compugen (CGEN) files $400M mixed securities shelf
Compugen Earnings Call Transcript: Q1 2026
Q1 2026 saw continued clinical and financial progress, with COM701 and partnered assets advancing in trials and a strong cash position supporting operations into 2029. Interim MAIA-ovarian trial data is expected in Q1 2027, and new rilvegostomig data will be presented at ASCO.
Compugen Earnings release: Q1 2026
Compugen released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
Compugen Registration statement: Registration filing
Compugen filed a registration statement on May 18, 2026, providing details about a securities offering with the SEC.
Compugen reports Q1 EPS (8c) vs. (8c) last year
Reports Q1 revenue $2.2M vs. $2.3M last year. Compugen (CGEN) expects that its cash and cash-related balances will be sufficient to fund its operating plans into 2029. The company has…
Compugen Reports First Quarter 2026 Results
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 Partner AstraZeneca is advancing rilvegostomig acr...
Compugen Slides: Corporate presentation
Compugen has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.